Replasia BV appears in FDA records as the applicant for HipStudio Analysis, a radiological image-processing system assigned product code LLZ under 21 CFR 892.2050. The clearance decision is dated September 22, 2026, with a Substantially Equivalent outcome and a Traditional submission type. The company's own published pages describe a Belgian medical technology developer working on patient-specific hip preservation tools for young adults, combining three-dimensional anatomical analysis with kinematic simulation. Distinguishing the applicant from related entities matters here: the clearance letter is addressed to Replasia BV care of a consultant identified with Replasia Aucto BV, and the FDA record lists Aucto BV alongside the applicant contact. [1][2][6][7]

The HipStudio Analysis clearance

FDA records identify HipStudio Analysis as the device name for K262442, filed by Replasia BV at Interleuvenlaan 62 Box 26, Leuven, Belgium, with Tim Van Cleynenbreugel as applicant contact. The record carries product code LLZ, regulation number 892.2050, device class 2, review panel Radiology, and a Summary statement. The decision is Substantially Equivalent, dated September 22, 2026, and the submission was not third-party reviewed. [1][6][7][8]

Dates in the public record do not fully agree. The FDA 510(k) dataset entry gives a date received of July 16, 2026, while the clearance letter states the submission was dated and received July 20, 2026. Both dates appear in the underlying documents, and the discrepancy is visible to anyone checking the filing. [1][2]

An Innolitics record adds that the device was developed under the name HipStudio Simulation Service and is marketed as HipStudio Analysis, and it lists attributes for AI/ML and Software as a Medical Device. The same record describes an indications statement for skeletally mature individuals suspected of a hip condition; that text is truncated in the available excerpt and should be read in full at the source. [8][9]

What the software does, per the manufacturer

Replasia's own product page states that HipStudio turns a routine CT into a patient-specific 3D hip model with automated morphology, coverage and version measurements, and that it is CE marked and FDA 510(k) cleared. The clearance letter describes a multi-step process: structures are segmented from grayscale images using Hounsfield units, texture and shape, three-dimensional models are calculated, and trained Replasia personnel then use proprietary HipStudio software to analyze joint morphology, run kinematic simulations and virtually simulate surgical or non-surgical hip preservation treatments. [2][3]

The company frames the product around describing deformity before treatment decisions, with surgical planning built on the patient's own anatomy. These are manufacturer descriptions of intended function, not independently verified performance claims. [3]

Company identity and the 3D-Shelf implant

Replasia describes itself as a Belgian medical technology company developing patient-specific solutions for hip preservation in young adults, bringing together experience in biomedical engineering, medical-device development, software, additive manufacturing, quality and regulatory affairs, and working with hip-preservation surgeons and clinical partners. Peter Mercelis is identified as CEO and co-founder. These characterizations come from the company's About page. [5]

The company's site lists a second product, the 3D-Shelf patient-specific implant, and states plainly that it is under clinical investigation and not commercially available. No FDA filing for 3D-Shelf appears among the records reviewed, so its regulatory status beyond that statement is unknown. [3][4]

Ownership and corporate structure are not established by these documents. The clearance letter is addressed to Replasia BV care of Carl Lierde, consultant for Replasia Aucto BV, and the FDA notification page also lists Aucto BV; the precise relationship between the two entities is not explained in the available text. The Leuven address is a filing address and should not be treated as a confirmed headquarters. [2][6]

Reading the filing record

The linked collection for Replasia BV contains one 510(k) record, K262442, and its decision count shows one Substantially Equivalent outcome. The smaller record sample likewise contains that single entry. These are counts of the filings assembled as of November 20, 2026, not measures of total company portfolio, sales or safety performance. [1]

Third-party indexes corroborate the core facts of the clearance, including applicant, product code, regulation, class, panel and decision date, and one index notes that its source data can change and that critical regulatory decisions should be verified against the official FDA source. [7][8]